Search Results - "Joseph Eron"

Selection Bias Due to Loss to Follow Up in Cohort Studies by Howe, Chanelle J., Cole, Stephen R., Lau, Bryan, Napravnik, Sonia, Joseph J., Eron

“…Selection bias due to loss to follow up represents a threat to the internal validity of estimates derived from cohort studies. Over the past 15 years,…”
Get full text

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society–USA Panel by Gandhi, Rajesh T, Bedimo, Roger, Hoy, Jennifer F, Landovitz, Raphael J, Smith, Davey M, Eaton, Ellen F, Lehmann, Clara, Springer, Sandra A, Sax, Paul E, Thompson, Melanie A, Benson, Constance A, Buchbinder, Susan P, del Rio, Carlos, Eron, Joseph J, Günthard, Huldrych F, Molina, Jean-Michel, Jacobsen, Donna M, Saag, Michael S

“…IMPORTANCE: Recent advances in treatment and prevention of HIV warrant updated recommendations to guide optimal practice. OBJECTIVE: Based on a critical…”
Get full text

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society–USA Panel by Saag, Michael S, Gandhi, Rajesh T, Hoy, Jennifer F, Landovitz, Raphael J, Thompson, Melanie A, Sax, Paul E, Smith, Davey M, Benson, Constance A, Buchbinder, Susan P, del Rio, Carlos, Eron, Joseph J, Fätkenheuer, Gerd, Günthard, Huldrych F, Molina, Jean-Michel, Jacobsen, Donna M, Volberding, Paul A

“…IMPORTANCE: Data on the use of antiretroviral drugs, including new drugs and formulations, for the treatment and prevention of HIV infection continue to guide…”
Get full text

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus by Fischer, 2nd, William A, Eron, Jr, Joseph J, Holman, Wayne, Cohen, Myron S, Fang, Lei, Szewczyk, Laura J, Sheahan, Timothy P, Baric, Ralph, Mollan, Katie R, Wolfe, Cameron R, Duke, Elizabeth R, Azizad, Masoud M, Borroto-Esoda, Katyna, Wohl, David A, Coombs, Robert W, James Loftis, Amy, Alabanza, Paul, Lipansky, Felicia, Painter, Wendy P

“…There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)…”
Get more information

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel by Saag, Michael S, Benson, Constance A, Gandhi, Rajesh T, Hoy, Jennifer F, Landovitz, Raphael J, Mugavero, Michael J, Sax, Paul E, Smith, Davey M, Thompson, Melanie A, Buchbinder, Susan P, del Rio, Carlos, Eron, Joseph J, Fätkenheuer, Gerd, Günthard, Huldrych F, Molina, Jean-Michel, Jacobsen, Donna M, Volberding, Paul A

“…IMPORTANCE: Antiretroviral therapy (ART) is the cornerstone of prevention and management of HIV infection. OBJECTIVE: To evaluate new data and treatments and…”
Get full text

Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies by Chugh, Pauline E, Sin, Sang-Hoon, Ozgur, Sezgin, Henry, David H, Menezes, Prema, Griffith, Jack, Eron, Joseph J, Damania, Blossom, Dittmer, Dirk P

“…MicroRNAs (miRNAs) are stable, small non-coding RNAs that modulate many downstream target genes. Recently, circulating miRNAs have been detected in various…”
Get full text

Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation by Gandhi, Rajesh T, McMahon, Deborah K, Bosch, Ronald J, Lalama, Christina M, Cyktor, Joshua C, Macatangay, Bernard J, Rinaldo, Charles R, Riddler, Sharon A, Hogg, Evelyn, Godfrey, Catherine, Collier, Ann C, Eron, Joseph J, Mellors, John W

“…Antiretroviral therapy (ART) reduces levels of HIV-1 and immune activation but both can persist despite clinically effective ART. The relationships among…”
Get full text

Curing HIV: Seeking to Target and Clear Persistent Infection by Margolis, David M., Archin, Nancie M., Cohen, Myron S., Eron, Joseph J., Ferrari, Guido, Garcia, J. Victor, Gay, Cynthia L., Goonetilleke, Nilu, Joseph, Sarah B., Swanstrom, Ronald, Turner, Anne-Marie W., Wahl, Angela

“…Human immunodeficiency virus type 1 (HIV-1) infection persists despite years of antiretroviral therapy (ART). To remove the stigma and burden of chronic…”
Get full text

Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies by Crooks, Amanda M., Bateson, Rosalie, Cope, Anna B., Dahl, Noelle P., Griggs, Morgan K., Kuruc, JoAnn D., Gay, Cynthia L., Eron, Joseph J., Margolis, David M., Bosch, Ronald J., Archin, Nancie M.

“…The quantitative viral outgrowth assay (QVOA) provides a precise minimal estimate of the reservoir of resting CD4⁺ T-cell infection (resting cell infection…”
Get full text

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials by Gupta, Samir K, Post, Frank A, Arribas, José R, Eron, Joseph J, Wohl, David A, Clarke, Amanda E, Sax, Paul E, Stellbrink, Hans-Jürgen, Esser, Stefan, Pozniak, Anton L, Podzamczer, Daniel, Waters, Laura, Orkin, Chloe, Rockstroh, Jürgen K, Mudrikova, Tatiana, Negredo, Eugenia, Elion, Richard A, Guo, Susan, Zhong, Lijie, Carter, Christoph, Martin, Hal, Brainard, Diana, SenGupta, Devi, Das, Moupali

“…OBJECTIVE:Compared with tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF) has been associated with improvement in markers of renal dysfunction…”
Get full text

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials by Raffi, François, Rachlis, Anita, Brinson, Cynthia, Arasteh, Keikawus, Górgolas, Miguel, Brennan, Clare, Pappa, Keith, Almond, Steve, Granier, Catherine, Nichols, W Garrett, Cuffe, Robert Liam, Jr, Joseph Eron, Walmsley, Sharon

“…OBJECTIVES:Dolutegravir (DTG) has been studied in three trials in HIV treatment-naive participants, showing noninferiority compared with raltegravir (RAL), and…”
Get full text

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial by Margolis, David A, Gonzalez-Garcia, Juan, Stellbrink, Hans-Jürgen, Eron, Joseph J, Yazdanpanah, Yazdan, Podzamczer, Daniel, Lutz, Thomas, Angel, Jonathan B, Richmond, Gary J, Clotet, Bonaventura, Gutierrez, Felix, Sloan, Louis, Clair, Marty St, Murray, Miranda, Ford, Susan L, Mrus, Joseph, Patel, Parul, Crauwels, Herta, Griffith, Sandy K, Sutton, Kenneth C, Dorey, David, Smith, Kimberly Y, Williams, Peter E, Spreen, William R

“…Cabotegravir and rilpivirine are antiretroviral drugs in development as long-acting injectable formulations. The LATTE-2 study evaluated long-acting…”
Get full text

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society–USA Panel by Günthard, Huldrych F, Saag, Michael S, Benson, Constance A, del Rio, Carlos, Eron, Joseph J, Gallant, Joel E, Hoy, Jennifer F, Mugavero, Michael J, Sax, Paul E, Thompson, Melanie A, Gandhi, Rajesh T, Landovitz, Raphael J, Smith, Davey M, Jacobsen, Donna M, Volberding, Paul A

“…IMPORTANCE: New data and therapeutic options warrant updated recommendations for the use of antiretroviral drugs (ARVs) to treat or to prevent HIV infection in…”
Get full text

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy by Gay, Cynthia L., Bosch, Ronald J, Ritz, Justin, Hataye, Jason M., Aga, Evgenia, Tressler, Randall L., Mason, Stephen W., Hwang, Carey K., Grasela, Dennis M., Ray, Neelanjana, Cyktor, Josh C., Coffin, John M., Acosta, Edward P., Koup, Richard A., Mellors, John W., Eron, Joseph J.

“…Background. Reversing immune exhaustion with an anti-PD-L1 antibody may improve human immunodeficiency virus type 1 (HIV-1)–specific immunity and increase…”
Get full text

Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial by Landovitz, Raphael J, Li, Sue, Eron, Joseph J, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Magnus, Manya, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A, Eshleman, Susan H, Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R, Margolis, David, Cohen, Myron S, McCauley, Marybeth, Hendrix, Craig W

“…Long-acting injectable cabotegravir is a novel integrase inhibitor currently in advanced clinical development for HIV prevention and treatment. We aimed to…”
Get full text

Generalizing evidence from randomized trials using inverse probability of sampling weights by Buchanan, Ashley L., Hudgens, Michael G., Cole, Stephen R., Mollan, Katie R., Sax, Paul E., Daar, Eric S., Adimora, Adaora A., Eron, Joseph J., Mugavero, Michael J.

“…Results obtained in randomized trials may not easily generalize to target populations. Whereas in randomized trials the treatment assignment mechanism is…”
Get full text

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial by Landovitz, Raphael J, Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Magnus, Manya, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A, Hendrix, Craig W, Eshleman, Susan H, Zhang, Yinfeng, Tolley, Elizabeth, Sugarman, Jeremy, Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R, Margolis, David, Spreen, William R, Cohen, Myron S, McCauley, Marybeth, Eron, Joseph J

“…Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an…”
Get full text

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV by Patel, Sonia Vibhakar, Jayaweera, Dushyantha T, Althoff, Keri N, Eron, Joseph J, Radtchenko, Janna, Mills, Anthony, Moyle, Graeme, Santiago, Steven, Sax, Paul E, Gillman, Jason, Mounzer, Karam, Elion, Richard A, Huhn, Gregory D

“…The advent of direct-acting antiviral (DAA) therapies has dramatically transformed HCV treatment, with most recent trials demonstrating high efficacy rates…”
Get full text

A week 48 randomized phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients by Eron, Joseph J, Orkin, Chloe, Gallant, Joel, Molina, Jean-Michel, Negredo, Eugenia, Antinori, Andrea, Mills, Anthony, Reynes, Jacques, Van Landuyt, Erika, Lathouwers, Erkki, Hufkens, Veerle, Jezorwski, John, Vanveggel, Simon, Opsomer, Magda

“…OBJECTIVES:To investigate efficacy and safety of a single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10…”
Get full text

Macrophages sustain HIV replication in vivo independently of T cells by Honeycutt, Jenna B, Wahl, Angela, Baker, Caroline, Spagnuolo, Rae Ann, Foster, John, Zakharova, Oksana, Wietgrefe, Stephen, Caro-Vegas, Carolina, Madden, Victoria, Sharpe, Garrett, Haase, Ashley T, Eron, Joseph J, Garcia, J Victor

“…Macrophages have long been considered to contribute to HIV infection of the CNS; however, a recent study has contradicted this early work and suggests that…”
Get full text